USA: Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York City; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; Rhode Island; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington, DC; Washington; West Virginia; Wisconsin; Wyoming
USA Territories: American Samoa (USA); Guam (USA); Puerto Rico (USA); Virgin Islands (USA); Northern Mariana Islands (USA)
USA Compact Free Associations: The Federated States of Micronesia (USA) Marshall Islands (USA) Republic of Palau (USA)
Canada: Alberta; British Columbia; Manitoba; New Brunswick; Newfoundland and Labrador; Northwest Territories; Nova Scotia; Nunavut; Ontario; Prince Edward Island; Quebec; Saskatchewan; Yukon
Israel
International country outside of the USA, Israel and Canada.
Opportunity for USA, Canada, and International research institutions in eligible countries to develop a Coronavirus (COVID-19) vaccine for low and middle-income countries. The purpose of the opportunity is to provide researchers with an existing vaccine as a foundation for further research and development. Requests from China, Hong Kong, Macau, and Taiwan are ineligible.
The intent of this RFP is to support COVID-19 vaccine development for LMICs. The support provided by Pfizer will be through the provision of the Pfizer-BioNTech COVID-19 Vaccine for comparator studies. No funding will be provided. Pfizer-BioNTech is particularly interested in supporting research in the following areas:
Estimated Size of Grant:
Anticipated Project Length: 1-2 years
Application: http://www.cybergrants.com/pfizer/Research
If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Derek Warnick (derek.warnick@pfizer.com), with the subject line “COVID-19 Vaccine Development in LMIC.”